Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.91
+$0.06 · +3.24%
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Previous close
$1.91
+$0.06 · +3.24%
Regular session · ET · Market data may be delayed.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Day range
Current $1.91
52-week range
Current $1.91
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
24
Expensive
Sentiment
68
Bullish
Risk
63
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Day range
Current $1.91
52-week range
Current $1.91
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 7.14M USD | 20.97M USD | 41.87M USD | 23.03M USD |
| Cost of goods sold | 95K USD | 812K USD | 6.43M USD | 7.51M USD | 1.55M USD |
| Gross profit | −95K USD | 6.33M USD | 14.54M USD | 34.35M USD | 21.47M USD |
| Research and development | 18.01M USD | 32.76M USD | 108.38M USD | 91.76M USD | 82.58M USD |
| Selling, general, and administrative | 8.74M USD | 26.39M USD | 27.65M USD | 30.13M USD | 27.98M USD |
| Operating expenses | 26.75M USD | 62.11M USD | 136.03M USD | 121.89M USD | 110.56M USD |
| Interest income | 1.38M USD | 2.83M USD | 1.32M USD | 654K USD | 603K USD |
| Interest expense | — | 8.47M USD | — | 3K USD | — |
| Depreciation and amortization | 95K USD | 192K USD | 259K USD | 1.67M USD | 1.55M USD |
| Operating income | −26.75M USD | −55.78M USD | −121.5M USD | −87.54M USD | −89.08M USD |
| Net income | −18.21M USD | −70.87M USD | −118.51M USD | −85.47M USD | −88.44M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.75
358.12% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
